Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs

Genes and Diseases

Volumn 2, Issue 2, 2015, Pages 152-163

  Safa, Ahmad R ^a,b   Saadatzadeh, Mohammad Reza ^a,b   Cohen Gadol, Aaron A ^b   Pollok, Karen E ^a,b   Bijangi Vishehsaraei, Khadijeh ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer stem cells; Dedifferentiation; Epigenetic; GBM plasticity; GBM stem cells; Glioblastoma; Stemness

Indexed keywords

MICRORNA; TRANSCRIPTION FACTOR;

CANCER STEM CELL; CELL DIFFERENTIATION; CELL HETEROGENEITY; CLONAL EVOLUTION; EPIGENETICS; GLIOBLASTOMA; GLIOBLASTOMA STEM CELL; HUMAN; NONHUMAN; PLASTICITY; REVIEW; TUMOR RECURRENCE;

EID: 84978148860     PISSN: None     EISSN: 23523042     Source Type: Journal    
DOI: 10.1016/j.gendis.2015.02.001     Document Type: Review

References (130)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics. CA Cancer J Clin 2005, 55:10-30.
2. Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
3. Hegi M.E., Diserens A.C., Godard S., et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004, 10:1871-1874.
4. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
5. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
6. Singh S.K., Hawkins C., Clarke I.D. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
7. Singh A.K., Arya R.K., Maheshwari S., et al. Tumor heterogeneity and cancer stem cell paradigm: updates in concept, controversies and clinical relevance. Int J Cancer 2014, 136:1991-2000.
8. Yan K., Yang K., Rich J.N. The evolving landscape of glioblastoma stem cells. Curr Opin Neurol 2013, 26:701-707.
9. Jackson M., Hassiotou F., Nowak A. Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target. Carcinogenesis 2015, 36:177-185.
10. Gao X., McDonald J.T., Naidu M., et al. A proposed quantitative index for assessing the potential contribution of reprogramming to cancer stem cell kinetics. Stem Cells Int 2014, 249309.
11. Louis D.N., Ohgaki H., Wiestler O.D., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109.
12. Carén H., Pollard S.M., Beck S. The good, the bad and the ugly: epigenetic mechanisms in glioblastoma. Mol Asp Med 2013, 34:849-862.
13. Hamaya K., Doi K., Tanaka T., et al. The determination of glial fibrillary acidic protein for the diagnosis and histogenetic study of central nervous system tumors: a study of 152 cases. Acta Med Okayama 1985, 39:453-462.
14. Jacque C.M., Vinner C., Kujas M., et al. Determination of glial fibrillary acidic protein (GFAP) in human brain tumors. Neurol Sci 1978, 35:147-155.
15. Masui K., Cloughesy T.F., Mischel P.S. Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol 2012, 38(3):271-291.
16. Kondo Y., Katsushima K., Ohka F., et al. Epigenetic dysregulation in glioma. Cancer Sci 2014, 105:363-369.
17. Appin C.L., Brat D.J. Molecular genetics of gliomas. Cancer J 2014, 20:66-72.
18. Cadieux B., Ching T.T., VandenBerg S.R., et al. Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Res 2006, 66:8469-8476.
19. Phillips H.S., Kharbanda S., Chen R., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157-173.
20. Verhaak R.G., Hoadley K.A., Purdom E., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
21. Leibetseder A., Ackerl M., Flechl B., et al. Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO). Neuro Oncol 2013, 15:112-121.
22. Popova S.N., Bergqvist M., Dimberg A., et al. Subtyping of gliomas of various WHO grades by the application of immunohistochemistry. Histopathology 2014, 64:365-379.
23. Vartanian A., Singh S.K., Agnihotri S., et al. GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity. Neuro Oncol 2014, 16:1167-1175.
24. Gill B.J., Pisapia D.J., Malone H.R., et al. MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Proc Natl Acad Sci U. S. A 2014, 111:12550-12555.
25. Sottoriva A., Spiteri I., Piccirillo S.G., et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U. S. A 2013, 110:4009-4014.
26. Stieber D., Golebiewska A., Evers L., et al. Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. Acta Neuropathol 2014, 127:203-219.
27. Meacham C.E., Morrison S.J. Tumour heterogeneity and cancer cell plasticity. Nature 2013, 501:328-337.
28. Vries R.G., Huch M., Clevers H. Stem cells and cancer of the stomach and intestine. Mol Oncol 2010, 4:373-384.
29. Humphries A., Cereser B., Gay L.J., et al. Lineage tracing reveals multipotent stem cells maintain human adenomas and the pattern of clonal expansion in tumor evolution. Proc Natl Acad Sci U. S. A 2013, 110:E2490-E2499.
30. Andor N., Harness J.V., Müller S., et al. EXPANDS: expanding ploidy and allele frequency on nested subpopulations. Bioinformatics 2014, 30:50-60.
31. Nakano I. Stem cell signature in glioblastoma: therapeutic development for a moving target. J Neurosurg 2014, 14:1-7.
32. Shackleton M., Quintana E., Fearon E.R., et al. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009, 138:822-829.
33. Goffart N., Kroonen J., Rogister B. Glioblastoma-initiating cells: relationship with neural stem cells and the micro-environment. Cancers (Basel) 2013, 5:1049-1071.
34. Tang D.G. Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012, 22:457-472.
35. Binda E., Reynolds B.A., Vescovi A.L. Glioma stem cells: turpis omen in nomen? (The evil in the name?). J Intern Med 2014, 276:25-40.
36. Lathia J.D., Heddleston J.M., Venere M., et al. Deadly teamwork: neural cancer stem cells and the tumor microenvironment. Cell Stem Cell 2011, 8:482-485.
37. Auffinger B., Tobias A.L., Han Y., et al. Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. Cell Death Differ 2014, 21:1119-1131.
38. Luo J., Zhou X., Yakisich J.S. Stemness and plasticity of lung cancer cells: paving the road for better therapy. Onco Targets Ther 2014, 7:1129-1134.
39. Dahan P., Martinez Gala J., Delmas C., et al. Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance. Cell Death Dis 2014, 5:e1543.
40. Friedmann-Morvinski D. Glioblastoma heterogeneity and cancer cell plasticity. Crit Rev Oncog 2014, 19:327-336.
41. Schepers A.G., Snippert H.J., Stange D.E., et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012, 337:730-735.
42. Driessens G. Deciphering tumor growth by clonal analysis. Crit Rev Oncog 2014, 19:317-325.
43. Cheng L., Huang Z., Zhou W., et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 2013, 153:139-152.
44. Wakimoto H., Mohapatra G., Kanai R., et al. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol 2012, 14:132-144.
45. Bayin N.S., Modrek A.S., Placantonakis D.G. Glioblastoma stem cells: molecular characteristics and therapeutic implications. World J Stem Cells 2014, 6:230-238.
46. Mao X.G., Yan M., Xue X.Y., et al. Overexpression of ZNF217 in glioblastoma contributes to the maintenance of glioma stem cells regulated by hypoxia-inducible factors. Lab Invest 2011, 91:1068-1078.
47. Motegi H., Kamoshima Y., Terasaka S., et al. Type 1 collagen as a potential niche component for CD133-positive glioblastoma cells. Neuropathology 2014, 34:378-385.
48. Denysenko T., Gennero L., Roos M.A., et al. Glioblastoma cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies. Cell Biochem Funct 2010, 28:343-351.
49. Brescia P., Ortensi B., Fornasari L., et al. CD133 is essential for glioblastoma stem cell maintenance. Stem Cells 2013, 31:857-869.
50. Gambelli F., Sasdelli F., Manini I., et al. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression. Neoplasia 2012, 14:150-158.
51. Jamal M., Rath B.H., Tsang P.S., et al. The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells. Stem Cells 2010, 28:5-16.
52. Fan X., Khaki L., Zhu T.S., et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Front Biosci (Elite Ed) 2011, 1:701-710.
53. Beier C.P., Beier D. CD133 negative cancer stem cells in glioblastoma. PLoS One 2009, 4:e6869.
54. Nishide K., Nakatani Y., Kiyonari H., et al. Glioblastoma formation from cell population depleted of Prominin1-expressing cells. PLoS One 2009, 4:e6869.
55. Lehnus K.S., Donovan L.K., Huang X., et al. CD133 glycosylation is enhanced by hypoxia in cultured glioma stem cells. Int J Oncol 2013, 42:1011-1017.
56. Denysenko T., Gennero L., Juenemann C., et al. Heterogeneous phenotype of human glioblastoma: invitro study. Cell Biochem Funct 2014, 32:164-176.
57. Liu X.J., Wu W.T., Wu W.H., et al. A minority subpopulation of CD133(+)/EGFRvIII(+)/EGFR(-) cells acquires stemness and contributes to gefitinib resistance. CNS Neurosci Ther 2013, 19:494-502.
58. Mao P., Joshi K., Li J., et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci U. S. A 2013, 110:8644-8649.
59. Scatena R., Bottoni P., Pontoglio A., et al. Cancer stem cells: the development of new cancer therapeutics. Expert Opin Biol Ther 2011, 11:875-892.
60. Kreso A., Dick J.E. Evolution of the cancer stem cell model. Cell Stem Cell 2014, 14:275-291.
61. Klevebring D., Rosin G., Ma R., et al. Sequencing of breast cancer stem cell populations indicates a dynamic conversion between differentiation states invivo. Breast Cancer Res 2014, 16:R72.
62. Berezovsky A.D., Poisson L.M., Cherba D., et al. Sox2 promotes malignancy in glioblastoma by regulating plasticity and astrocytic differentiation. Neoplasia 2014, 16:193-206.
63. Jun H.J., Bronson R.T., Charest A. Inhibition of EGFR induces a c-MET-driven stem cell population in glioblastoma. Stem Cells 2014, 32:338-348.
64. Gao X., Jin W. The emerging role of tumor-suppressive microRNA-218 in targeting glioblastoma stemness. Cancer Lett 2014, 353:25-31.
65. Li Y., Laterra J. Cancer stem cells: distinct entities or dynamically regulated phenotypes?. Cancer Res 2012, 72:576-580.
66. Soeda A., Park M., Lee D., et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009, 28:3949-3959.
67. Pistollato F., Abbadi S., Rampazzo E., et al. Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells 2010, 28:851-862.
68. Chaffer C.L., Brueckmann I., Scheel C., et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U. S. A 2011, 108:7950-7955.
69. Marjanovic N.D., Weinberg R.A., Chaffer C.L. Cell plasticity and heterogeneity in cancer. Clin Chem 2013, 59:168-179.
70. Bao S., Wu Q., McLendon R.E., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
71. Chen J., Fu X., Wan Y., et al. miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1. Tumour Biol 2014, 35:6293-6302.
72. Riganti C., Salaroglio I.C., Caldera V., et al. Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway. Neuro Oncol 2013, 15:1502-1517.
73. Beier D., Röhrl S., Pillai D.R., et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 2008, 68:5706-5715.
74. Fouse S.D., Nakamura J.L., James C.D., et al. Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype. Neuro Oncol 2014, 16:361-371.
75. Pointer K.B., Clark P.A., Zorniak M., et al. Glioblastoma cancer stem cells: biomarker and therapeutic advances. Neurochem Int 2014, 71:1-7.
76. Beier D., Schulz J.B., Beier C.P. Chemoresistance of glioblastoma cancer stem cells-much more complex than expected. Mol Cancer 2011, 10:128.
77. Yang G., Quan Y., Wang W., et al. Dynamic equilibrium between cancer stem cells and non-stem cancer cells in human SW620 and MCF-7 cancer cell populations. Br J Cancer 2012, 106:1512-1519.
78. Zhu H., Wang D., Liu Y., et al. Role of the Hypoxia-inducible factor-1 alpha induced autophagy in the conversion of non-stem pancreatic cancer cells into CD133+ pancreatic cancer stem-like cells. Cancer Cell Int 2013, 13:119.
79. Bayin N.S., Modrek A.S., Placantonakis D.G., et al. Glioblastoma stem cells: molecular characteristics and therapeutic implications. World J Stem Cells 2014, 6:230-238.
80. Hide T., Kuratsu J. Progress in the study of brain tumor stem cells as treatment targets. Brain Nerve 2009, 61:781-789.
81. Schiffer D., Mellai M., Annovazzi L., et al. Stem cell niches in glioblastoma: a neuropathological view. Biomed Res Int 2014, 2014:725921.
82. Finer S., Holland M.L., Nanty L., et al. The hunt for the epiallele. Environ Mol Mutagen 2011, 52:1-11.
83. Easwaran H., Tsai H.C., Baylin S.B. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 2014, 54:716-727.
84. Ting A.H., McGarvey K.M., Baylin S.B. The cancer epigenome-components and functional correlates. Genes Dev 2006, 20:3215-3231.
85. Gronych J., Pfister S.M., Jones D.T. Connect four with glioblastoma stem cell factors. Cell 2014, 157:525-527.
86. Suvà M.L., Rheinbay E., Gillespie S.M., et al. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell 2014, 157:580-594.
87. Joshi K., Banasavadi-Siddegowda Y., Mo X., et al. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells 2013, 31:1051-1063.
88. Cho Y.S., Kang Y., Kim K., et al. The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor. Biochem Biophys Res Commun 2014, 447:7-11.
89. Minata M., Gu C., Joshi K., et al. Multi-kinase inhibitor C1 triggers mitotic catastrophe of glioma stem cells mainly through MELK kinase inhibition. PLoS One 2014, 9:e92546.
90. Chudnovsky Y., Kim D., Zheng S., et al. ZFHX4 interacts with the NuRD core memberCHD4 and regulates the glioblastoma tumor-initiating cell state. Cell Rep 30 Jan 2014, 6:313-324.
91. Mathews L.A., Crea F., Farrar W.L. Epigenetic gene regulation in stem cells and correlation to cancer. Differentiation 2009, 78:1-17.
92. Gil J., O'Loghlen A. PRC1 complex diversity: where is it taking us?. Trends Cell Biol 2014, 24:632-641.
93. Kim E., Kim M., Woo D.H., et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 2013, 23:839-852.
94. Asuthkar S., Velpula K.K., Chetty C., et al. Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity. Oncotarget 2012, 3:1439-1454.
95. Gao X., Jin W. The emerging role of tumor-suppressive microRNA-218 in targeting glioblastoma stemness. Cancer Lett 2014, 353:25-31.
96. Chu P.M., Ma H.I., Chen L.H., et al. Deregulated microRNAs identified in isolated glioblastoma stem cells: an overview. Cell Transpl 2013, 22:741-753.
97. Bier A., Giladi N., Kronfeld N., et al. MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget 2013, 4:665-676.
98. Lee H.K., Bier A., Cazacu S., et al. MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor. PLoS One 2013, 8:e54652.
99. Yao Y., Ma J., Xue Y., et al. MiR-449a exerts tumor-suppressive functions in human glioblastoma by targeting Myc-associated zinc-finger protein. Mol Oncol 2015, 9(3):640-656.
100. Fazi F., Blandino G. MicroRNAs: non coding pleiotropic factors in development, cancer prevention and treatment. Microrna 2013, 2:81.
101. Ma J., Yao Y., Wang P., et al. MiR-152 functions as a tumor suppressor in glioblastoma stem cells by targeting Krüppel-like factor 4. Cancer Lett 2014, 355:85-95.
102. Shang C., Guo Y., Hong Y., et al. MiR-21 up-regulation mediates glioblastoma cancer stem cells apoptosis and proliferation by targeting FASLG. Mol Biol Rep 2015, 721-727.
103. Rathod S.S., Rani S.B., Khan M. Tumor suppressive miRNA-34a suppresses cell proliferation and tumor growth of glioma stem cells by targeting Akt and Wnt signaling pathways. FEBS Open Bio 2014, 4:485-495.
104. González-Gómez P., Sánchez P., Mira H., et al. MicroRNAs as regulators of neural stem cell-related pathways in glioblastoma multiforme. Mol Neurobiol 2011, 44:235-249.
105. Liu J., Albrecht A.M., Ni X., et al. Glioblastoma tumor initiating cells: therapeutic strategies targeting apoptosis and microRNA pathways. Curr Mol Med 2013, 13:352-357.
106. Liu Q., Nguyen D.H., Dong Q., et al. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neurooncol 2009, 94:1-19.
107. Ruan J., Lou S., Dai Q., et al. Tumor suppressor miR-181c attenuates proliferation, invasion, and self-renewal abilities in glioblastoma. Neuroreport 2015, 26(2):66-73.
108. Tezcan G., Tunca B., Bekar A., et al. microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells. Cell Mol Neurobiol 2014, 34(5):679-692.
109. Tezcan G., Tunca B., Bekar A., et al. Olea europaea leaf extract improves the treatment response of GBM stem cells by modulating miRNA expression. Am J Cancer Res 2014, 4:572-590.
110. Godlewski J., Nowicki M.O., Bronisz A., et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 2008, 68:9125-9130.
111. Peruzzi P., Bronisz A., Nowicki M.O., et al. MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells. Neuro Oncol 2013, 15:1212-1224.
112. Schonberg D.L., Lubelski D., Miller T.E., et al. Brain tumor stem cells: molecular characteristics and their impact on therapy. Mol Asp Med 2014, 39:82-101.
113. Nabilsi N.H., Deleyrolle L.P., Darst R.P., et al. Multiplex mapping of chromatin accessibility and DNA methylation within targeted single molecules identifies epigenetic heterogeneity in neural stem cells and glioblastoma. Genome Res 2014, 24:329-339.
114. Natsume A., Ito M., Katsushima K., et al. Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma. Cancer Res 2013, 73:4559-4570.
115. Lopez-Bertoni H., Lal B., Li A., et al. DNMT-dependent suppression of microRNA regulates the induction of GBM tumor-propagating phenotype by Oct4 and Sox2. Oncogene 2014, [Epub ahead of print].
116. Del Vecchio C.A., Giacomini C.P., Vogel H., et al. EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. Oncogene 2013, 32:2670-2681.
117. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
118. Baylin S.B., Esteller M., Rountree M.R., et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001, 10:687-692.
119. Christman J.K. 5-Azacytidine and 5-aza-2-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002, 21:5483-5495.
120. So A.Y., Jung J.W., Lee S., et al. DNA methyltransferase controls stem cell aging by regulating BMI1 and EZH2 through microRNAs. PLoS One 2011, 6:e19503.
121. Chang H.W., Wang H.C., Chen C.Y. 5-azacytidine induces anoikis, inhibits mammosphere formation and reduces metalloproteinase 9 activity in MCF-7 human breast cancer cells. Molecules 2014, 19:3149-3159.
122. Witt O., Deubzer H.E., Milde T., et al. HDAC family: what are the cancer relevant targets?. Cancer Lett 2009, 277:8-21.
123. Tabouret E., Chinot O., Sanson M., et al. Predictive biomarkers investigated in glioblastoma. Expert Rev Mol Diagn 2014, 14:883-893.
124. Connolly R., Stearns V. Epigenetics as a therapeutic target in breast cancer. J Mammary Gland Biol Neoplasia 2012, 17:191-204.
125. Jiang P., Mukthavaram R., Chao Y. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. J Transl Med 2014, 12:13.
126. Hothi P., Martins T.J., Chen L., et al. High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells. Oncotarget 2012, 3:1124-1136.
127. Paranjpe A., Zhang R., Ali-Osman F., et al. Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage. Carcinogenesis 2014, 35:692-702.
128. Alvarez A.A., Field M., Bushnev S., et al. The effects of histone deacetylase inhibitors on glioblastoma-derived stem cells. J Mol Neurosci 2015, 55:7-20.
129. Dror N., Mandel M., Lavie G. Unique anti-glioblastoma activities of hypericin are at the crossroad of biochemical and epigenetic events and culminate in tumor cell differentiation. PLoS One 2013, 8:e73625.
130. Katsushima K., Kondo Y. Non-coding RNAs as epigenetic regulator of glioma stem-like cell differentiation. Front Genet 3 Feb 2014, 5:14.